Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 410,154 shares, an increase of 186.5% from the May 31st total of 143,168 shares. Approximately 4.9% of the shares of the company are sold short. Based on an average trading volume of 108,694 shares, the days-to-cover ratio is currently 3.8 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC bought a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma as of its most recent SEC filing. 6.72% of the stock is currently owned by institutional investors.

Cocrystal Pharma Stock Up 1.0%

COCP traded up $0.01 during midday trading on Monday, hitting $1.03. 51,471 shares of the company were exchanged, compared to its average volume of 1,285,763. The firm’s 50 day moving average price is $1.19 and its 200-day moving average price is $1.11. Cocrystal Pharma has a 1-year low of $0.86 and a 1-year high of $2.67. The firm has a market capitalization of $14.20 million, a P/E ratio of -1.41 and a beta of 1.42.

Cocrystal Pharma (NASDAQ:COCP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.23 million. On average, sell-side analysts predict that Cocrystal Pharma will post -0.69 earnings per share for the current fiscal year.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.